Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure - On July 18, 2025, Barnes & Noble disclosed that there may be an overstatement of up to $23.0 million in its accounts receivable balance as of the fiscal year-end on May 3, 2025, due to issues related to the recording of digital sales costs [3]. - Following this disclosure, Barnes & Noble's share price fell by $2.36, or approximately 21%, closing at $8.87 per share on July 21, 2025 [3]. Legal Context - The investigation by Kirby McInerney LLP focuses on whether Barnes & Noble and/or its officers have engaged in unlawful business practices that could affect shareholders [1][4]. - The law firm specializes in securities litigation and has a history of recovering billions of dollars for shareholders [6].

Core Points - Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited complied with federal securities laws following a subpoena from the U.S. Securities and Exchange Commission regarding the company's disclosures on prostate cancer therapeutic candidates [1] - The announcement of the subpoena led to a decline in Telix's stock price [1] Company Information - Telix Pharmaceuticals Limited is publicly traded on NASDAQ under the ticker TLX [1] - The company is involved in the development of therapeutic candidates for prostate cancer [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their OptionsIf you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 a ...

Core Viewpoint - Neogen Corporation is facing a securities class action lawsuit for failing to disclose material information during the class period from January 5, 2023, to June 3, 2025, which has led to significant financial losses for investors [1][3]. Company Performance - On April 9, 2025, Neogen reported a quarterly revenue decrease of 3.4% to $221 million, attributed to integration issues, and lowered its FY25 guidance, anticipating capital expenditures of $100 million due to reduced adjusted EBITDA and integration-related costs [4]. - Following the revenue report, Neogen's share price dropped 28% to close at $5.02 per share on a volume of 47 million shares [4]. - On June 4, 2025, the company projected an EBITDA margin in the high-teens, a significant decline from the previous quarter's profit margin of 22%, resulting in an additional 17% drop in share price to close at $4.96 per share [4]. Legal Context - The lawsuit is titled Operating Eng'rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802, and is pending in the United States District Court for the Western District of Michigan [5]. - Investors who purchased shares during the class period have until September 16, 2025, to file lead plaintiff applications [1][2].

Core Points - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] - The lawsuit claims that Capricor made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3] - Following the CRL announcement, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [4] Company Information - Capricor Therapeutics is involved in developing cell therapies, specifically targeting conditions like cardiomyopathy associated with DMD [2] - The company faced significant challenges with the FDA regarding its lead drug candidate, deramiocel, which has implications for its future development and market potential [3] Legal Context - The class action lawsuit allows investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, to seek recovery for losses incurred due to the alleged misleading statements [1][4] - Investors have until September 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]

Core Points - Holzer & Holzer, LLC is investigating Capricor Therapeutics, Inc. for potential compliance issues with federal securities laws following the receipt of a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel [1] - The announcement of the CRL led to a decline in Capricor's stock price [1] Company Information - Capricor Therapeutics, Inc. trades on NASDAQ under the ticker CAPR [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Viewpoint - A class action securities lawsuit has been filed against Bitfarms Ltd. alleging securities fraud that affected investors between March 21, 2023, and December 9, 2024 [1][2]. Group 1: Allegations and Financial Misstatements - The lawsuit claims that Bitfarms had inadequate internal controls over financial reporting [2]. - It is alleged that the company misclassified proceeds from the sale of digital assets, categorizing them as cash flow from operating activities instead of investing activities [2]. - The complaint states that Bitfarms overstated its ability to remediate material weaknesses in its internal controls related to the classification of the 2021 Warrants [2]. - These errors led to misstatements in several previously issued financial statements, which are now deemed inaccurate and likely to require restatement [2]. - As a result, the company's public statements were materially false and misleading during the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Bitfarms Ltd. during the specified timeframe have until July 8, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction following the acquisition of Dermavant [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Financial Impact and Stock Performance - Organon provided positive statements about its capital allocation strategy, emphasizing regular dividends as a top priority, while concealing adverse facts about its financial priorities [5]. - Following the revelation of these misleading statements, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Petco Health and Wellness Company, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by August 29, 2025 [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Petco between January 14, 2021, and June 5, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Petco, and the firm is reminding investors of the deadline to seek the role of lead plaintiff [3][5]. - The complaint alleges that Petco and its executives made false and misleading statements regarding the sustainability of its business model and the strength of its product strategy [5]. Group 2: Financial Performance - On June 5, 2025, Petco reported net sales of $1.5 billion for the first quarter of 2025, reflecting a 2.3% year-over-year decline [6]. - Following the financial results announcement, Petco's stock price dropped by $0.85 per share, or 23.34%, closing at $2.78 per share on June 6, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth and business strategy [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal rights [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [2]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in customer volume [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].